Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
53
AME Quote, Financials, Valuation and Earnings
Last price:
$179.74
Seasonality move
:
0.15%
Day range:
$176.69 - $179.84
52-week range:
$145.02 - $198.33
Dividend yield:
0.66%
P/E ratio:
29.41x
P/S ratio:
6.01x
P/B ratio:
4.16x
Volume:
1.2M
Avg. volume:
1.3M
1-year change:
2.67%
Market cap:
$41.5B
Revenue:
$6.9B
EPS (TTM):
$6.11
Analysts' Opinion
-
Consensus RatingAMETEK has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 5 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $193.89, AMETEK has an estimated upside of 7.9% from its current price of $179.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $158.00 representing 12.08% downside risk from its current price of $179.70.
Fair Value
-
According to the consensus of 16 analysts, AMETEK has 7.9% upside to fair value with a price target of $193.89 per share.
AME vs. S&P 500
-
Over the past 5 trading days, AMETEK has underperformed the S&P 500 by -1.55% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
AMETEK does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AMETEK revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter AMETEK reported revenues of $1.7B.
Earnings Growth
-
AMETEK has grown year-over-year earnings for 2 quarters straight. In the most recent quarter AMETEK reported earnings per share of $1.52.
Enterprise value:
43B
EV / Invested capital:
--
Price / LTM sales:
6.01x
EV / EBIT:
23.75x
EV / Revenue:
6.20x
PEG ratio (5yr expected):
3.98x
EV / Free cash flow:
25.10x
Price / Operating cash flow:
24.33x
Enterprise value / EBITDA:
19.53x
Gross Profit (TTM):
$2.5B
Return On Assets:
9.58%
Net Income Margin (TTM):
20.43%
Return On Equity:
14.95%
Return On Invested Capital:
11.94%
Operating Margin:
26.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $6.3B | $6.7B | $6.9B | $1.7B | $1.7B | |
| Gross Profit | $2.2B | $2.4B | $2.5B | $591.5M | $625M | |
| Operating Income | $1.6B | $1.7B | $1.8B | $417.2M | $454.8M | |
| EBITDA | $1.9B | $2.1B | $2.2B | $514.6M | $559.6M | |
| Diluted EPS | $5.16 | $5.69 | $6.11 | $1.34 | $1.52 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.6B | $2.3B | $2.7B | $2.8B | $2.8B | |
| Total Assets | $10.6B | $12B | $12.6B | $14.9B | $14.9B | |
| Current Liabilities | $1.1B | $1.6B | $1.5B | $2.5B | $2B | |
| Total Liabilities | $4.5B | $5B | $4.9B | $5.9B | $4.9B | |
| Total Equity | $6.1B | $6.9B | $7.8B | $9B | $10B | |
| Total Debt | $2.4B | $2.5B | $2.2B | $2.9B | $1.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.3B | $1.8B | $1.8B | $410.2M | $417.5M | |
| Cash From Investing | -$660M | -$2.3B | -$349.1M | -$21.4M | -$125.7M | |
| Cash From Financing | -$603.2M | $494.7M | -$1.5B | -$417.5M | -$277.7M | |
| Free Cash Flow | $1.2B | $1.6B | $1.7B | $382.6M | $394.5M | |
AME
Sector
Market Cap
$41.5B
$611.3M
Price % of 52-Week High
90.61%
81.21%
Dividend Yield
0.66%
0%
Shareholder Yield
1.93%
2.28%
1-Year Price Total Return
2.67%
-1.12%
Beta (5-Year)
1.093
0.761
Dividend yield:
0.66%
Annualized payout:
$1.12
Payout ratio:
18.74%
Growth streak:
5 years
Technicals
8-day SMA
Sell
Level
$179.70
200-day SMA
Buy
Level
$178.72
Bollinger Bands (100)
Buy
Level
166.67 - 183.67
Chaikin Money Flow
Buy
Level
517.2M
20-day SMA
Sell
Level
$179.97
Relative Strength Index (RSI14)
Buy
Level
51.01
ADX Line
Sell
Level
14.05
Williams %R
Neutral
Level
-46.9819
50-day SMA
Buy
Level
$178.69
MACD (12, 26)
Buy
Level
0.27
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
400.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.9886)
Buy
CA Score
(Annual)
Level (0.8087)
Buy
Beneish M-Score
(Annual)
Level (-2.5974)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-2.377)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Founded in 1930 and transformed over the decades through the acquisition of dozens of esteemed brands, Ametek owns a collection of over 40 autonomous industrial businesses operating within the research, aerospace, energy, medical, and manufacturing industries. Ametek segments its business into two operating groups: the electronic instruments group and the electromechanical group. The EIG sells a broad portfolio of analytical, test, and measurement instruments, while the EMG sells highly engineered components, interconnects, and specialty metals. The company emphasizes product differentiation and market leadership in the niche markets where it operates.
Stock Forecast FAQ
In the current month, AME has received 10 Buy ratings 5 Hold ratings, and 1 Sell ratings. The AME average analyst price target in the past 3 months is $193.89.
-
Where Will AMETEK Stock Be In 1 Year?
According to analysts, the consensus estimate is that AMETEK share price will rise to $193.89 per share over the next 12 months.
-
What Do Analysts Say About AMETEK?
Analysts are divided on their view about AMETEK share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AMETEK is a Sell and believe this share price will drop from its current level to $158.00.
-
What Is AMETEK's Price Target?
The price target for AMETEK over the next 1-year time period is forecast to be $193.89 according to 16 Wall Street analysts, 10 of them rate the stock a Buy, 1 rates the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is AME A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AMETEK is a Buy. 10 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AME?
You can purchase shares of AMETEK via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AMETEK shares.
-
What Is The AMETEK Share Price Today?
AMETEK was last trading at $179.74 per share. This represents the most recent stock quote for AMETEK. Yesterday, AMETEK closed at $179.70 per share.
-
How To Buy AMETEK Stock Online?
In order to purchase AMETEK stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
93
EXOD alert for Jul 18
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
